Background Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared
with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in …

Bruton tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape
for patients with B-cell malignancies, including chronic lymphocytic leukemia, Waldenstrom …

Aptamers or chemical antibodies are single-stranded DNA or RNA oligonucleotides that
bind proteins and small molecules with high affinity and specificity by recognizing tertiary or …

Chronic lymphocytic leukemia (CLL) is characterized by chronic clonal expansion of mature
CD19-expressing B lymphocytes and global dysfunction of immune effectors, including …

Cancer pathogenesis involves the interplay of tumor-and microenvironment-derived stimuli.
Here we focused on the influence of an immunomodulatory cell type, myeloid-derived …

The bone marrow microenvironment promotes proliferation and drug resistance in chronic
lymphocytic leukemia (CLL). Although ibrutinib is active in CLL, it is rarely able to clear …

Abstract Purpose: PI3K inhibitors (PI3Ki) are approved for relapsed chronic lymphocytic
leukemia (CLL). Although patients may show an initial response to these therapies …

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic B
lymphocytes with high levels of Wnt5a in the plasma. Currently, the cell source of Wnt5a …

Simple Summary Since the identification of a large variety of biomarkers in B cell
malignancies as being driving factors for tumor progression and patient prognosis, their …

Background Chronic lymphocytic leukemia (CLL) is one of the most frequent occurring types
of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. At …